MiR-1225-5p acts as tumor suppressor in glioblastoma via targeting FNDC3B

Abstract

This study attempted to research the molecular mechanism underlying the inhibitory role of miR-1225-5p in the malignant progression of glioblastoma. Bioinformatics analyses based on the gene expression omnibus (GEO) and Chinese glioma genome atlas (CGGA) databases showed that miR-1225-5p, as a favorable prognostic factor, was expressed at low levels in glioblastoma, and its expression was also related to WHO grade and age. The subsequent CCK-8 assay indicated that miR-1225-5p might prevent the malignant progression of glioblastoma, which was represented by that miR-1225-5p mimic reduced the viability of glioblastoma cells. Then, we predicted that FNDC3B might be a potential target gene of miR-1225-5p, and it was negatively correlated with the level of miR-1225-5p, which were confirmed by dual-luciferase reporter assay, qRT-PCR and western blot assays. Moreover, based on the analyses of the cancer genome atlas (TCGA), Oncomine and CGGA databases, FNDC3B was enriched in glioblastoma and high expression of FNDC3B led to poor prognosis. Finally, CCK8 and transwell experiments showed that the ability of miR-1225-5p to inhibit glioblastoma cell viability, invasion and migration was at least partially achieved by targeting FNDC3B. In general, these results revealed that the miR-1225-5p/FNDC3B axis contributes to inhibiting the malignant phenotype of glioblastoma cells, which lays a foundation for molecular diagnosis and treatment of glioblastoma.

FNDC3B is a Potential Prognostic Biomarker and Correlated With Immune Infiltrates in Glioma

“…In the present study, we found that FNDC3B was highly expressed in glioma tissues by mining multiple databases, and the expression levels of FNDC3B increased with the level of the malignant degree, which was also con rmed in another study [12]. These results suggested that FNDC3B could serve as a promising molecular marker for predicting the degree of malignancy in brain glioma.…”

“…Notably, a few studies have demonstrated that FNDC3B expression levels are correlated with glioblastoma. Wang and Xu reported that MiR-1225-5p and MiR-129-5p inhibit the malignant glioblastoma cells via targeting FNDC3B [12,13]. Furthermore, a newly integrated analysis of RNA binding proteins in glioma revealed that FNDC3B can not only serve as a useful prognostic biomarker but also promote glioma cell proliferation [14].…”

Hsa_circRNA_0001971 contributes to oral squamous cell carcinoma progression via miR‐186‐5p/Fibronectin type III domain containing 3B axis

“…Fibronectin type III domain containing 3B (FNDC3B) has been identified as a modulator of osteoblast and adipocyte differentiation. 19 In recent years, many evidence proved the positive role of FNDC3B in colorectal cancer, 30 cervical cancer, 31 glioblastoma, 32 and tongue squamous cell carcinoma cells. 19 However, FNDC3B has not been explored in OSCC.…”

Expression Profile of Exosome-associated MicroRNA Derived from Human Red Blood Cell Suspensions During Storage: Predicting microRNA-1246 and microRNA-150-3p Exert Essential Roles in Transfusion-related Immunomodulation

“…Such as in dilated cardiomyopathy (DCM), miRNA-3064-5p, miRNA-6849-5p and miRNA-4701-3p were upregulated in abnormal activated CD4 + T cells which may be associated with the proliferation of CD4 + T cells [24]. MiRNA-1225-5p displays various impacts on the growth, invasion and metastasis of different malignancies by targeting speci c proteins [25,26,27]. MiRNA-3064-5p, which upregulated more than 20 times during RBC suspension storage helped to inhibit the development of hepatocellular carcinoma through angiogenesis suppression, which might provide potential molecular therapy for tumors [28].…”